Abstract:The tumor suppressor p53 is central to hematopoietic stem cell function. Loss of p53 function is associated with poor prognosis of acute myeloid leukemia (AML). P53 negative regulator MDM2 is frequently overexpressed in AML, thus it becomes an attractive therapeutic target for the treatment of AML with wild-type p53 (Wt-p53). Targeting MDM2 to restore p53 activity has been assessed in AML, but clinical outcomes are less promising. Notably, p53-mutated AML still lacks effective treatment approaches. Therefore, our study strived to explore potent therapeutics to target AML with p53 wild-type and mutations. Triptolide (TPL), an ancient herbal medicine, has been used to treat immune disorders for centuries. Accumulating evidence including ours have proven that low dose of TPL potentiates the efficacy of chemotherapies in a broad range of tumor types. In this study, we evaluated the anti-leukemic efficacy of combining low dose TPL with Nutlin3a, a MDM2 inhibitor, against AML with p53 wild-type and mutations. We found that low-dose TPL synergized with Nutlin3a to induce mitochondrial apoptosis in AML cells with Wt-p53 bothin vitroandin vivo. Underlying mechanism for the synergy showed that Nutlin3a upregulated pro-apoptosis factors (e.g. PUMA, p21), while low-dose TPL suppressed MDM2 transcription and reduced anti-apoptosis proteins (e.g. XIAP, Mcl-1) in Wt-p53 AML cells. Interestingly, we also observed that TPL but not Nutlin3a induced cell death in p53 shRNA knockdown, p53 deficiency cell lines (e.g. THP-1, HL-60) and primary samples. Thus, the p53-independent role of TPL was consequently focused. Our RNA-Seq analysis identified 621 differential expression genes (DEGs) after TPL treatment. These genes, including MYC, ATF4 and 4EBP1, were enriched in intrinsic apoptosis pathway responding to ER stress and thus we concluded that Triptolide played its p53 independent role via MYC-ATF4 axis. Collectively, these findings suggest that coadministration of Nutlin3a with low dose TPL would benefit for AML patients. Disclosures Carter: AstraZeneca:Research Funding;Syndax:Research Funding;Ascentage:Research Funding;Amgen:Research Funding. OffLabel Disclosure: Triptolide (TPL), an ancient herbal medicine, is applying to treat immune disorders.

Triptolide-Assisted Phosphorylation of p53 Suppresses Inflammation-Induced NF-κB Survival Pathways in Cancer Cells.

Inhibition of nonsense-mediated decay rescues p53/ isoform expression and activates the p53 pathway in and select-mutant cancers

Inhibition of Nonsense-Mediated Decay Rescues P53β/γ Isoform Expression and Activates the P53 Pathway in MDM2-overexpressing and Select P53-Mutant Cancers

Role Of P38 Mapk In Enhanced Human Cancer Cells Killing By The Combination Of Aspirin And Abt-737

Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells

Triptolide Induces Apoptosis in Human Anaplastic Thyroid Carcinoma Cells by A P53-Independent but Nf-Kappa B-Related Mechanism

NF-κB signaling inhibition and anticancer activities of LLDT-246 on human colorectal cancer HCT-116 cells in vitro.

Triptolide downregulates Rac1 and the JAK/STAT3 pathway and inhibits colitis-related colon cancer progression

Triptolide Enhances Chemotherapeutic Efficacy of Antitumor Drugs in Non-Small-cell Lung Cancer Cells by Inhibiting Nrf2-ARE Activity

Antagonist Effect of Triptolide on Akt Activation by Truncated Retinoid X Receptor-Alpha

Pharmacological Activation of the P53 Pathway Within the Tumor Microenvironment Induces Immunogenic Cell Death of Tumors and Enhances Antitumor Immunity

Triptolide Induces Growth Inhibition And Apoptosis Of Human Laryngocarcinoma Cells By Enhancing P53 Activities And Suppressing E6-Mediated P53 Degradation

Selective tumor cell killing by triptolide in p53 wild-type and p53 mutant ovarian carcinomas

Low-Dose Triptolide Promotes MDM2 Inhibitor Nutlin3a to Induce Acute Myeloid Leukemia Cell Death Via P53-Dependent and -Independent Mechanisms

Stabilization of P53 is a Novel Mechanism for Proapoptotic Function of NF-κB

Triptolide Induced Cell Death Through Apoptosis and Autophagy in Murine Leukemia WEHI‐3 Cells in Vitro and Promoting Immune Responses in WEHI‐3 Generated Leukemia Mice in Vivo

Mutant p53 suppresses innate immune signaling to promote tumorigenesis

Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade

Triptolide Induces Apoptosis of Gastric Cancer Cells Via Inhibiting the Overexpression of MDM2.

Triptolide Prevents Bone Loss Via Suppressing Osteoclastogenesis Through Inhibiting PI3K‐AKT‐NFATc1 Pathway

Triptolide induces apoptosis through the calcium/calmodulin‑dependent protein kinase kinaseβ/AMP‑activated protein kinase signaling pathway in non‑small cell lung cancer cells.